X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to focus on identifying subjects that could derive benefit from AN2025 (buparlisib) treatment in metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) patients and will expand to other indications and clinical trials.
Lead Product(s): Buparlisib,Paclitaxel
Therapeutic Area: Oncology Product Name: AN2025
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Adlai Nortye
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 31, 2023
Details:
A phase 2 study evaluated the efficacy of Debio 1562 (naratuximab emtansine), an anti-CD37 ADC, in combination with rituximab, in patients with R/R DLBCL. Deep learning models were used to extract spatial features from digitized slides stained with CD37 and CD20.
Lead Product(s): Naratuximab Emtansine,Rituximab
Therapeutic Area: Oncology Product Name: Debio 1562
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
